SCHEMBL7751687

SCHEMBL7751687

CCCCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.93
MAPT P10636 7/20 0.93
KMT2A Q03164 7/20 0.93
CYP3A4 P08684 6/20 0.93
MEN1 O00255 6/20 0.93
ESR1 P03372 6/20 0.93
TP53 P04637 3/20 0.93
ALOX15 P16050 3/20 0.93
SMN1; SMN2 Q16637 3/20 0.93
PGR P06401 3/20 0.93
AR P10275 3/20 0.93
ADORA3 P0DMS8 2/20 0.93
PTGS1 P23219 2/20 0.93
PDE3A Q14432 2/20 0.93
POLB P06746 1/20 0.93
CHRM1 P11229 1/20 0.93
TBXA2R P21731 1/20 0.93
ATM Q13315 1/20 0.93
USP2 O75604 1/20 0.93
MAPK1 P28482 3/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9418881 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Enanthate SCHEMBL28129756 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL1315378 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Enanthate SCHEMBL547096 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL3500119 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Undecylate SCHEMBL23728444 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Undecylate SCHEMBL453172 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL11596845 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL17419452 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Valerate SCHEMBL6195972 0.96 LMNA (1.00) LMNAMAPTKMT2ACYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 US disclosed
WO-2023223235-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF PURNA PHARMACEUTICALS NV (BE) 2023-11-23 WO disclosed
US-20160008376-A1 Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders BIOCOPEA LIMITED (GB) 2016-01-14 US disclosed
WO-2016005599-A1 COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS BIOCOPEA LIMITED (GB) 2016-01-14 WO disclosed
US-6265147-B1 DETECTING MODULATORS OF BRAIN ACTIVITY; MIX MODULATOR WITH RECEPTORS AND DETECT ACTIVATION OF RECEPTORS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2001-07-24 US disclosed
WO-2001039780-A1 ACTIVATION OF NOVEL ESTROGEN RECEPTOR SUPPORTS NEURONAL VIABILITY AND FUNCTION THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR LMNA 796/4885MAPT 4293/4885KMT2A 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.